{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:57:48Z","timestamp":1793642268415,"version":"4.5.1"},"reference-count":130,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"unspecified","delay-in-days":3303,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. psychiatr."],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Second-generation antipsychotics (SGA) are being used more often than ever before in children and adolescents with psychotic and a wide range of non-psychotic disorders. Several SGA have received regulatory approval for some paediatric indications in various countries, but off-label use is still frequent. The aim of this paper was to perform a systematic review and critically evaluate the literature on cardiometabolic and endocrine side-effects of SGA in children and adolescents through a Medline\/Pubmed\/Google Scholar search of randomized, placebo controlled trials of antipsychotics in children and adolescents (&lt;18 years old) until February 2010. In total, 31 randomized, controlled studies including 3595 paediatric patients were identified. A review of these data confirmed that SGA are associated with relevant cardiometabolic and endocrine side-effects, and that children and adolescents have a high liability to experience antipsychotic induced hyperprolactinaemia, weight gain and associated metabolic disturbances. Only weight change data were sufficiently reported to conduct a formal meta-analysis. In 24 trials of 3048 paediatric patients with varying ages and diagnoses, ziprasidone was associated with the lowest weight gain (\u22120.04 kg, 95% confidence interval [CI]: \u22120.38 to +0.30), followed by aripiprazole (0.79 kg, 95% CI: 0.54 to 1.04], quetiapine (1.43 kg, 95% CI: 1.17 to 1.69) and risperidone (1.76 kg, 95% CI: 1.27 to 2.25) were intermediate, and olanzapine was associated with weight gain the most (3.45 kg, 95% CI: 2.93 to 3.97). Significant weight gain appeared to be more prevalent in patients with autistic disorder who were also younger and likely less exposed to antipsychotics previously. These data clearly suggest that close screening and monitoring of metabolic side effects is warranted and that the least cardiometabolically problematic agents should be used first whenever possible. A good collaboration between child- and adolescent psychiatrists, general practitioners and paediatricians is essential to maximize overall outcomes and to reduce the likelihood of premature cardiovascular morbidity and mortality.<\/jats:p>","DOI":"10.1016\/j.eurpsy.2010.09.011","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T09:18:43Z","timestamp":1296811123000},"page":"144-158","source":"Crossref","is-referenced-by-count":302,"title":["Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice"],"prefix":"10.1017","volume":"26","author":[{"given":"M.","family":"De Hert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dobbelaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"S0924933800069315_bib0127","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1001\/jama.2009.1558","article-title":"Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents.","volume":"302","author":"Varley","year":"2009","journal-title":"JAMA"},{"key":"S0924933800069315_bib0126","doi-asserted-by":"publisher","DOI":"10.1089\/104454601750143348"},{"key":"S0924933800069315_bib0124","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04726"},{"key":"S0924933800069315_bib0128","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2004.00444.x"},{"key":"S0924933800069315_bib0123","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1176\/appi.ajp.2007.06111932","article-title":"Olanzapine versus placebo in the treatment of adolescents with bipolar mania.","volume":"164","author":"Tohen","year":"2007","journal-title":"Am J Psychiatry"},{"key":"S0924933800069315_bib0122","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S0033291709990407","article-title":"Weight gain in antipsychotic-na\u00efve patients: a review and meta-analysis.","volume":"40","author":"Tarricone","year":"2010","journal-title":"Psychol Med"},{"key":"S0924933800069315_bib0114","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"key":"S0924933800069315_bib0118","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200209000-00002"},{"key":"S0924933800069315_bib0112","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055434.39968.67"},{"key":"S0924933800069315_bib0111","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":"Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study.","volume":"39","author":"Sallee","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"S0924933800069315_bib0104","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"key":"S0924933800069315_bib0101","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.6.679"},{"key":"S0924933800069315_bib0099","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.78"},{"key":"S0924933800069315_bib0048","first-page":"9","article-title":"Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.","volume":"69","author":"Findling","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"S0924933800069315_bib0097","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.jcp.0000142281.85207.d5","article-title":"The atypical antipsychotic therapy and metabolic issues national survey.","volume":"24","author":"Newcomer","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"S0924933800069315_bib0084","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.21"},{"key":"S0924933800069315_bib0092","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2010.48"},{"key":"S0924933800069315_bib0091","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2009.179"},{"key":"S0924933800069315_bib0087","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.7.1050"},{"key":"S0924933800069315_bib0085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013171"},{"key":"S0924933800069315_bib0082","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e3181b76658"},{"key":"S0924933800069315_bib0113","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08r04392"},{"key":"S0924933800069315_bib0129","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/ijo.2009.222","article-title":"The role of GNAS and other imprinted genes in the development of obesity.","volume":"34","author":"Weinstein","year":"2010","journal-title":"Int J Obes"},{"key":"S0924933800069315_bib0105","first-page":"124","article-title":"First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.","volume":"19","author":"Panagiotopoulos","year":"2010","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"S0924933800069315_bib0077","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"S0924933800069315_bib0093","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2010.00797.x"},{"key":"S0924933800069315_bib0074","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m03538"},{"key":"S0924933800069315_bib0072","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.12.2072"},{"key":"S0924933800069315_bib0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.02.032"},{"key":"S0924933800069315_bib0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2005.12.006"},{"key":"S0924933800069315_bib0121","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283320511"},{"key":"S0924933800069315_bib0052","first-page":"1","article-title":"Antipsychotica en seksuele stoornissen.","volume":"7","author":"Floris","year":"2001","journal-title":"Neuron"},{"key":"S0924933800069315_bib0068","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2008.11.010"},{"key":"S0924933800069315_bib0110","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.0120"},{"key":"S0924933800069315_bib0107","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.03.025"},{"key":"S0924933800069315_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.79.1.1","article-title":"Report of the second task force on blood pressure control in children 1987.","volume":"79","author":"Horan","year":"1987","journal-title":"Pediatrics"},{"key":"S0924933800069315_bib0061","first-page":"43","article-title":"Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia.","volume":"22","author":"Hanssens","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"S0924933800069315_bib0130","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60958-1"},{"key":"S0924933800069315_bib0059","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464200-00003"},{"key":"S0924933800069315_bib0062","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1176\/appi.ajp.2008.08030383","article-title":"Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.","volume":"166","author":"Haupt","year":"2009","journal-title":"Am J Psychiatry"},{"key":"S0924933800069315_bib0058","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.0144"},{"key":"S0924933800069315_bib0056","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00750.x"},{"key":"S0924933800069315_bib0036","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1399-5618.2009.00728.x","article-title":"A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder.","volume":"11","author":"DelBello","year":"2009","journal-title":"Bipolar Disord"},{"key":"S0924933800069315_bib0035","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.008"},{"key":"S0924933800069315_bib0034","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0520"},{"key":"S0924933800069315_bib0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.04.010"},{"key":"S0924933800069315_bib0033","doi-asserted-by":"crossref","unstructured":"[33] De Hert, M , Vancampfort, D , Correll, CU , Mercken, V , Peuskens, J , Sweers, K , van Winkel, R , Mitchell, A . A systematic evaluation and comparison of the guidelines for screening and monitoring of cardiometabolic risk in people with schizophrenia. Br J Psychiatry 2010; submitted.","DOI":"10.1192\/bjp.bp.110.084665"},{"key":"S0924933800069315_bib0119","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.5.629"},{"key":"S0924933800069315_bib0090","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2337\/dc08-1720","article-title":"Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.","volume":"32","author":"Morrato","year":"2009","journal-title":"Diabetes Care"},{"key":"S0924933800069315_bib0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2009.01.005"},{"key":"S0924933800069315_bib0108","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2008"},{"key":"S0924933800069315_bib0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.01.028"},{"key":"S0924933800069315_bib0029","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.4088\/JCP.v67n1208","article-title":"Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder.","volume":"67","author":"De Hert","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"S0924933800069315_bib0089","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0219"},{"key":"S0924933800069315_bib0069","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60486-9"},{"key":"S0924933800069315_bib0022","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e318040b25f"},{"key":"S0924933800069315_bib0079","doi-asserted-by":"publisher","DOI":"10.1177\/000992280404300504"},{"key":"S0924933800069315_bib0073","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e3181900404"},{"key":"S0924933800069315_bib0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.06.044"},{"key":"S0924933800069315_bib0006","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes.","volume":"27","author":"American Diabetes Association","year":"2004","journal-title":"Diabetes Care"},{"key":"S0924933800069315_bib0038","doi-asserted-by":"crossref","unstructured":"[38] Dobbelaere M, De Hert M. Metabole en endocriene bijwerkingen van atypische antipsychotica bij kinderen en jongeren. Richtlijnen voor de klinische praktijk. Tijdschr Geneesk 2010;66(14\u201315):705\u201312.","DOI":"10.47671\/TVG.66.14-15.2000795"},{"key":"S0924933800069315_bib0014","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0405"},{"key":"S0924933800069315_bib0125","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2010.03.011"},{"key":"S0924933800069315_bib0051","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1089\/cap.2006.16.308","article-title":"Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics.","volume":"16","author":"Fleischhaker","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"S0924933800069315_bib0080","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1517\/14656566.7.13.1825","article-title":"Sertindole: efficacy and safety in schizophrenia.","volume":"7","author":"Lindstr\u00f6m","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"S0924933800069315_bib0055","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/08039488.2010.500397","article-title":"Swedish Clinical Guidelines Prevention and management of metabolic risk in patients with severe psychiatric disorders.","volume":"64","author":"Gothefors","year":"2010","journal-title":"Nord J Psychiatry"},{"key":"S0924933800069315_bib0020","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000220851.94392.30"},{"key":"S0924933800069315_bib0116","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":"A pilot study of risperidone, olanzapine and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"S0924933800069315_bib0066","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2008.07007"},{"key":"S0924933800069315_bib0001","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-007-9139-6"},{"key":"S0924933800069315_bib0015","first-page":"579","article-title":"Preventie en behandeling van somatische complicaties bij antipsychoticagebruik.","volume":"50","author":"Cahn","year":"2008","journal-title":"Tijdschr Psychiatr"},{"key":"S0924933800069315_bib0004","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.8.1337"},{"key":"S0924933800069315_bib0053","unstructured":"[53] Food and Drug Administration. Pediatric indications. www.fda.gov\/..\/CommitteesMeetingMaterials\/Drugs\/PsychopharmacologicDrugsAdvisoryCommittee\/UCM164423.pdf; accessed 01 06 2010."},{"key":"S0924933800069315_bib0103","first-page":"311","article-title":"Antipsychotics and metabolic abnormalities in children and adolescents: a review of the literature and some recommendations.","volume":"52","author":"Overbeek","year":"2010","journal-title":"Tijdschr Psychiatr"},{"key":"S0924933800069315_bib0027","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.4088\/JCP.v69n0716","article-title":"Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.","volume":"69","author":"Croarkin","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"S0924933800069315_bib0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.02.808"},{"key":"S0924933800069315_bib0002","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis.","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"S0924933800069315_bib0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","article-title":"Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.","volume":"47","author":"Correll","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"S0924933800069315_bib0026","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2010.00798.x"},{"key":"S0924933800069315_bib0044","first-page":"10","article-title":"Dosing of atypical antipsychotics in children and adolescents.","volume":"5","author":"Findling","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"S0924933800069315_bib0096","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4002066"},{"key":"S0924933800069315_bib0018","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721120-00006"},{"key":"S0924933800069315_bib0005","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/cap.2005.15.869","article-title":"Acute and long-term safety and tolerability of risperidone in children with autism. J Child.","volume":"15","author":"Aman","year":"2005","journal-title":"Adolesc Psychopharmacol"},{"key":"S0924933800069315_bib0037","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1399-5618.2010.00796.x","article-title":"Primum non nocere: balancing the risks and benefits of prescribing psychotropic medications for youth with bipolar disorder.","volume":"12","author":"DelBello","year":"2010","journal-title":"Bipolar Disorders"},{"key":"S0924933800069315_bib0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.09.024"},{"key":"S0924933800069315_bib0009","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with non-fasting triglycerides and risk of cardiovascular events in women.","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"S0924933800069315_bib0039","doi-asserted-by":"publisher","DOI":"10.1097\/01.mop.0000151714.87702.a9"},{"key":"S0924933800069315_bib0109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s007870070015","article-title":"Atypical neuroleptics in child and adolescent psychiatry.","volume":"9","author":"Remschmidt","year":"2000","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"S0924933800069315_bib0067","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-006-0580-1"},{"key":"S0924933800069315_bib0102","first-page":"13","article-title":"Trends in antipsychotic drug use by very young, privately insured children.","volume":"49","author":"Olfson","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"S0924933800069315_bib0086","first-page":"15","article-title":"Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.","volume":"69","author":"McDougle","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"S0924933800069315_bib0063","doi-asserted-by":"publisher","DOI":"10.1089\/10445460152595559"},{"key":"S0924933800069315_bib0043","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00004583-200004000-00021","article-title":"A double-blind pilot study of risperidone in the treatment of conduct disorder.","volume":"39","author":"Findling","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"S0924933800069315_bib0094","doi-asserted-by":"publisher","DOI":"10.1177\/08830738060210060801"},{"key":"S0924933800069315_bib0047","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05164yel"},{"key":"S0924933800069315_bib0008","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e3180323354"},{"key":"S0924933800069315_bib0010","doi-asserted-by":"publisher","DOI":"10.2165\/11530020-000000000-00000"},{"key":"S0924933800069315_bib0049","first-page":"583","article-title":"Double-blind maintenance safety and effectiveness findings from the treatment of early-onset schizophrenia spectrum (TEOSS) study.","volume":"49","author":"Findling","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"S0924933800069315_bib0076","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000162572.25203.7e"},{"key":"S0924933800069315_bib0083","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200620100-00005"},{"key":"S0924933800069315_bib0070","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.14.1871"},{"key":"S0924933800069315_bib0081","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.575"},{"key":"S0924933800069315_bib0046","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.07061035"},{"key":"S0924933800069315_bib0115","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.094"},{"key":"S0924933800069315_bib0012","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"key":"S0924933800069315_bib0019","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4088\/JCP.09ac05255","article-title":"Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need.","volume":"70","author":"Cohen","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"S0924933800069315_bib0078","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08030368"},{"key":"S0924933800069315_bib0064","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.541"},{"key":"S0924933800069315_bib0041","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.5.6.713"},{"key":"S0924933800069315_bib0054","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0717"},{"key":"S0924933800069315_bib0024","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/09540260801889179","article-title":"Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients.","volume":"20","author":"Correll","year":"2008","journal-title":"Int Rev Psychiatry"},{"key":"S0924933800069315_bib0060","doi-asserted-by":"publisher","DOI":"10.3109\/10401230209147453"},{"key":"S0924933800069315_bib0025","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"S0924933800069315_bib0057","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1192\/bjp.bp.107.046177","article-title":"Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study.","volume":"194","author":"Haas","year":"2009","journal-title":"Br J Psychiatry"},{"key":"S0924933800069315_bib0028","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1542\/peds.2008-1349","article-title":"Lipid screening and cardiovascular health in childhood.","volume":"122","author":"Daniels","year":"2008","journal-title":"Pediatrics"},{"key":"S0924933800069315_bib0106","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2004.14.359"},{"key":"S0924933800069315_bib0003","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00023210-200822070-00002","article-title":"Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders. A systematic critical reappraisal.","volume":"22","author":"Alvarez-Jimenez","year":"2008","journal-title":"CNS Drugs"},{"key":"S0924933800069315_bib0098","first-page":"32","article-title":"Preliminary results of the MEAC study: metabolic effects of antipsychotics in children.","volume":"35","author":"Nicol","year":"2009","journal-title":"Schizophr Bull"},{"key":"S0924933800069315_bib0100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"S0924933800069315_bib0088","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2008.01317.x","article-title":"The metabolic syndrome and schizophrenia.","volume":"119","author":"Meyer","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"S0924933800069315_bib0040","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301051"},{"key":"S0924933800069315_bib0017","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/cap.2004.14.372","article-title":"Second-generation antipsychotic medications in children and adolescents. J Child.","volume":"14","author":"Cheng-Shannon","year":"2004","journal-title":"Adolesc Psychopharmacol"},{"key":"S0924933800069315_bib0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2004.06.006"},{"key":"S0924933800069315_bib0045","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1113"},{"key":"S0924933800069315_bib0021","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chc.2005.08.007","article-title":"Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.","volume":"15","author":"Correll","year":"2006","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"S0924933800069315_bib0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.schres.2006.06.026","article-title":"Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.","volume":"86","author":"Nasrallah","year":"2006","journal-title":"Schizophr Res"},{"key":"S0924933800069315_bib0120","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200406010-00003"},{"key":"S0924933800069315_bib0075","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbm109"},{"key":"S0924933800069315_bib0031","first-page":"15","article-title":"Metabolic syndrome in people with schizophrenia: a review.","volume":"8","author":"De Hert","year":"2009","journal-title":"Schizophr Res"},{"key":"S0924933800069315_bib0117","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08050756"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933810001999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933810001999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933800069315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T21:07:44Z","timestamp":1712178464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933800069315\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":130,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0924933800069315"],"URL":"https:\/\/doi.org\/10.1016\/j.eurpsy.2010.09.011","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}